ES2130167T3 - Un sistema para la eliminacion mejorada in vivo de agentes de diagnostico y/o agentes terapeuticos por agotamiento extracorpores de los agentes. - Google Patents
Un sistema para la eliminacion mejorada in vivo de agentes de diagnostico y/o agentes terapeuticos por agotamiento extracorpores de los agentes.Info
- Publication number
- ES2130167T3 ES2130167T3 ES92903020T ES92903020T ES2130167T3 ES 2130167 T3 ES2130167 T3 ES 2130167T3 ES 92903020 T ES92903020 T ES 92903020T ES 92903020 T ES92903020 T ES 92903020T ES 2130167 T3 ES2130167 T3 ES 2130167T3
- Authority
- ES
- Spain
- Prior art keywords
- agents
- extracorports
- exhaustion
- vivo
- diagnostic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Nanotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
SE DESCRIBE UN METODO Y UN SISTEMA PARA REDUCIR EN ANFITRIONES VERTEBRADOS, LOS NIVELES NO OBJETIVOS DE MOLECULAS ESPECIFICAS DESTINADAS AL DIAGNOSTICO Y/O APLICACIONES TERAPEUTICAS, EN DONDE DICHAS MOLECULAS SE ADMINISTRAN A UN ANFITRION VERTEBRADO Y SE MANTIENEN EN EL MISMO POR UN CIERTO TIEMPO, PARA QUE SE CONCENTREN EN EL OBJETIVO POR AGREGACION AL MISMO. LAS MOLECULAS QUE NO SE AGREGAN AL OBJETIVO SE EXTRAEN DEL SISTEMA DE CIRCULACION SANGUINEA O AL MENOS SE REDUCEN A UNA CONCENTRACION MENOR, PASANDO LA SANGRE A TRAVES DE UN DISPOSITIVO EXTRACORPOREO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9100142A SE9100142L (sv) | 1991-01-17 | 1991-01-17 | En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2130167T3 true ES2130167T3 (es) | 1999-07-01 |
Family
ID=20381639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES92903020T Expired - Lifetime ES2130167T3 (es) | 1991-01-17 | 1992-01-15 | Un sistema para la eliminacion mejorada in vivo de agentes de diagnostico y/o agentes terapeuticos por agotamiento extracorpores de los agentes. |
Country Status (10)
Country | Link |
---|---|
US (2) | US6251394B1 (es) |
EP (1) | EP0567514B1 (es) |
JP (1) | JP3471352B2 (es) |
AT (1) | ATE178214T1 (es) |
CA (1) | CA2100256C (es) |
DE (1) | DE69228802T2 (es) |
DK (1) | DK0567514T3 (es) |
ES (1) | ES2130167T3 (es) |
SE (1) | SE9100142L (es) |
WO (1) | WO1992012730A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6075010A (en) * | 1992-06-09 | 2000-06-13 | Neorx Corporation | Small molecular weight ligand-hexose containing clearing agents |
US6416738B1 (en) | 1973-12-07 | 2002-07-09 | Neorx Corporation | Pretargeting methods and compounds |
DK0436717T3 (da) * | 1989-08-02 | 2003-05-05 | Mitra Medical Technology Ab | System til anvendelse ved en fremgangsmåde til terapeutisk eller diagnostisk behandling |
US6358490B2 (en) | 1992-06-09 | 2002-03-19 | Neorx Corporation | Three-step pretargeting methods and compounds |
US6217869B1 (en) | 1992-06-09 | 2001-04-17 | Neorx Corporation | Pretargeting methods and compounds |
US5911969A (en) | 1992-06-09 | 1999-06-15 | Neorx Corporation | Pretargeting protocols for enhanced localization of active agents to target sites |
WO1995015978A1 (en) * | 1993-12-07 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
US6015897A (en) * | 1993-12-07 | 2000-01-18 | Neorx Corporation | Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota |
WO1995025540A1 (en) * | 1994-03-23 | 1995-09-28 | Alexion Pharmaceuticals, Inc. | Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation |
US6172045B1 (en) | 1994-12-07 | 2001-01-09 | Neorx Corporation | Cluster clearing agents |
US6908903B1 (en) | 1994-12-07 | 2005-06-21 | Aletheon Pharmaceuticals, Inc. | Cluster clearing agents |
AU730388B2 (en) * | 1996-01-11 | 2001-03-08 | Peregrine Pharmaceuticals, Inc. | Antibodies with reduced net positive charge |
US20010023288A1 (en) | 1999-07-07 | 2001-09-20 | Wilbur D. Scott | Trifunctional reagent for conjugation to a biomolecule |
PT1049499E (pt) | 1998-01-20 | 2004-03-31 | Mitra Medical Technology Ab | Aparelho para uso na extraccao de elementos especialmente anticorpos exogenos presentes no sangue ou no plasma |
US6533734B1 (en) * | 1999-06-11 | 2003-03-18 | The Board Of Trustees Of The University Of Illinois | Time-integrated sampler of bodily fluid |
IT1310933B1 (it) * | 1999-11-16 | 2002-02-27 | Luigi Benatti | Macchina multifunzionale per il monitoraggio ed il controllo diterapie locoregionali in oncologia. |
SE0002287D0 (sv) * | 2000-06-16 | 2000-06-16 | Department Of Radiation Oncolo | Biotinderivat |
AU7476101A (en) * | 2000-06-16 | 2001-12-24 | Department Of Radiation Oncolo | Biotin derivatives |
WO2003012396A2 (en) * | 2001-08-01 | 2003-02-13 | Chauhan Anil K | Immune complexes |
WO2003090781A1 (en) * | 2002-04-23 | 2003-11-06 | Meir Strahilevitz | Methods and devices for targeting a site in a mammal and for removing species from a mammal |
US20040077985A1 (en) * | 2002-09-03 | 2004-04-22 | Donnie Rudd | Method of replenishing cells damaged by treatment for cancer |
US20040044300A1 (en) * | 2002-09-03 | 2004-03-04 | Donnie Rudd | Method of replenishing cells damaged by treatment for cancer |
WO2004071446A2 (en) * | 2003-02-12 | 2004-08-26 | Chauhan Anil K | Immune complexes |
US20080075704A1 (en) * | 2005-02-28 | 2008-03-27 | Wolf David A | Method of providing readily available cellular material derived from peripheral blood, and a composition thereof |
BRPI0607883A2 (pt) * | 2005-02-28 | 2009-12-22 | Regenetech Inc | método para obter material celular prontamente disponìvel derivado de sangue periférico e uma composição do referido material celular |
US20110014151A1 (en) * | 2006-01-11 | 2011-01-20 | Biotech Igg Ab | Macromolecule conjugate |
WO2012142180A1 (en) * | 2011-04-12 | 2012-10-18 | Tianxin Wang | Methods to detect and treat diseases |
US9549953B2 (en) * | 2011-12-08 | 2017-01-24 | Eliaz Therapeutics, Inc. | Galectin-3 plasmapheresis therapy |
WO2013123432A2 (en) | 2012-02-16 | 2013-08-22 | Atyr Pharma, Inc. | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases |
CN105378075B (zh) | 2013-03-15 | 2022-04-05 | Atyr 医药公司 | 组氨酰-trna合成酶-fc缀合物 |
JP2020517638A (ja) | 2017-04-20 | 2020-06-18 | エータイアー ファーマ, インコーポレイテッド | 肺の炎症を治療するための組成物および方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4375414A (en) | 1971-05-20 | 1983-03-01 | Meir Strahilevitz | Immunological methods for removing species from the blood circulatory system and devices therefor |
US4371515A (en) | 1978-12-26 | 1983-02-01 | E-Y Laboratories, Inc. | Method for forming an isolated lectin-immunological conjugate |
US4223672A (en) | 1979-02-08 | 1980-09-23 | Baxter Travenol Laboratories, Inc. | Variable volume plasma treatment chamber for an apparatus for the extracorporeal treatment of disease |
US4215688A (en) | 1979-02-09 | 1980-08-05 | Baxter Travenol Laboratories, Inc. | Apparatus for the extracorporeal treatment of disease |
US4350156A (en) | 1980-05-29 | 1982-09-21 | Japan Foundation For Artificial Organs | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
US4824432A (en) | 1981-03-24 | 1989-04-25 | S.V.S. Laboratories, Inc. | Method for treating AIDS and other immune deficiencies and immune disorders |
US4687808A (en) | 1982-08-12 | 1987-08-18 | Biospecific Technologies, Inc. | Activation of biocompatible polymers with biologicals whose binding complements are pathological effectors |
CA1221307A (en) * | 1982-12-02 | 1987-05-05 | Nobutaka Tani | Adsorbent and process for preparing the same |
CA1236738A (en) | 1983-06-01 | 1988-05-17 | Mark R. Honard | Therapeutic device |
US4551435A (en) | 1983-08-24 | 1985-11-05 | Immunicon, Inc. | Selective removal of immunospecifically recognizable substances from solution |
US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
US4877599A (en) | 1986-11-10 | 1989-10-31 | New England Deaconess Hospital Corporation | Detection of vascular disease with labelled antibodies |
US5122112A (en) * | 1986-11-21 | 1992-06-16 | Imre Corporation | Antigen-specific removal of circulating immune complexes |
US4800016A (en) | 1986-11-24 | 1989-01-24 | The University Of Michigan | Extracorporeal blood de-heparinization system |
DE3705637A1 (de) * | 1987-02-21 | 1988-09-29 | Bissendorf Peptide Gmbh | Vorrichtung zur entfernung von lokal applizierten wirkstoffen gegen solide tumoren |
US4846786A (en) | 1987-04-30 | 1989-07-11 | Massachusetts Institute Of Technology | Bioreactor containing suspended, immobilized species |
US4885207A (en) * | 1987-07-13 | 1989-12-05 | Uop | Biocompatible protein or ligand immobilization system |
US4865841A (en) | 1987-10-23 | 1989-09-12 | Imre Corporation | Methods and compositions for transient elimination of humoral immune antibodies |
US5069662A (en) * | 1988-10-21 | 1991-12-03 | Delcath Systems, Inc. | Cancer treatment |
US5149425A (en) | 1988-11-09 | 1992-09-22 | Chembiomed, Ltd. | Affinity supports for hemoperfusion |
KR0185967B1 (ko) | 1989-01-23 | 1999-05-01 | 에프. 쥐. 엠. 헤르만스; 에이. 쥐. 제이. 베르미렌 | 치료용 약물의 부위 특이적 생체내 활성작용 |
US5252466A (en) * | 1989-05-19 | 1993-10-12 | Biotechnology Research And Development Corporation | Fusion proteins having a site for in vivo post-translation modification and methods of making and purifying them |
JP2922641B2 (ja) | 1989-08-02 | 1999-07-26 | コーベ ラボラトリーズ,インコーポレーテッド | 医学的薬剤による治療法 |
DK0436717T3 (da) * | 1989-08-02 | 2003-05-05 | Mitra Medical Technology Ab | System til anvendelse ved en fremgangsmåde til terapeutisk eller diagnostisk behandling |
AU8366398A (en) | 1998-07-07 | 2000-01-24 | Department Of Radiation Oncology University Of Washington | Trifunctional reagent for conjugation to a biomolecule |
-
1991
- 1991-01-17 SE SE9100142A patent/SE9100142L/xx not_active Application Discontinuation
-
1992
- 1992-01-15 AT AT92903020T patent/ATE178214T1/de not_active IP Right Cessation
- 1992-01-15 EP EP92903020A patent/EP0567514B1/en not_active Expired - Lifetime
- 1992-01-15 CA CA002100256A patent/CA2100256C/en not_active Expired - Lifetime
- 1992-01-15 WO PCT/SE1992/000020 patent/WO1992012730A1/en active IP Right Grant
- 1992-01-15 JP JP50311992A patent/JP3471352B2/ja not_active Expired - Fee Related
- 1992-01-15 US US08/090,047 patent/US6251394B1/en not_active Expired - Fee Related
- 1992-01-15 DE DE69228802T patent/DE69228802T2/de not_active Expired - Lifetime
- 1992-01-15 DK DK92903020T patent/DK0567514T3/da active
- 1992-01-15 ES ES92903020T patent/ES2130167T3/es not_active Expired - Lifetime
-
2000
- 2000-10-12 US US09/689,421 patent/US6723318B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH06504542A (ja) | 1994-05-26 |
SE9100142L (sv) | 1992-07-18 |
CA2100256C (en) | 2004-06-08 |
DE69228802T2 (de) | 1999-10-14 |
EP0567514B1 (en) | 1999-03-31 |
SE9100142D0 (sv) | 1991-01-17 |
DK0567514T3 (da) | 1999-10-18 |
CA2100256A1 (en) | 1992-07-18 |
ATE178214T1 (de) | 1999-04-15 |
DE69228802D1 (de) | 1999-05-06 |
US6251394B1 (en) | 2001-06-26 |
EP0567514A1 (en) | 1993-11-03 |
JP3471352B2 (ja) | 2003-12-02 |
WO1992012730A1 (en) | 1992-08-06 |
US6723318B1 (en) | 2004-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2130167T3 (es) | Un sistema para la eliminacion mejorada in vivo de agentes de diagnostico y/o agentes terapeuticos por agotamiento extracorpores de los agentes. | |
ES2188580T3 (es) | Sistema para uso en un metodo de tratamiento terapeutico o de diagnostico. | |
RU94038043A (ru) | Применение замещенных производных аденина для лечения множественного склероза | |
DE68922456D1 (de) | Krebsbehandlung. | |
ES2022329B3 (es) | Bloque de bomba para interconectar una camara de irradiacion con un sistema de tratamiento de pacientes por fotoactivacion | |
BR9713979A (pt) | Processos e aparelhos para a formação de imagem de um volume particular de tecido de planta ou de animal e para diagnóstico médico | |
IT1151636B (it) | Metodo e sistema per il trattamento extracorporeo del sangue | |
ES2078986T3 (es) | Sistema para controlar un tratamiento medico, por ejemplo dialisis. | |
DE3587941D1 (de) | Gerät zur vorläufigen reperfusionsbehandlung von herzanfallsymptomen. | |
SE9404196D0 (sv) | New antithrombotic formulation | |
DK47089D0 (da) | Middel med oedelaeggende virkning paa maligne tumorer, fremgangsmaade til fremstilling af saadanne midler og anvendelse af disse til terapeutisk behandling af cancer | |
SE8602743L (sv) | Bruksferdiga injektionslosningar innehallande en antitumorantracyklinglykosid | |
SE9202506D0 (sv) | System foer beredning av en medicinsk loesning t ex foer dialys | |
KR930700163A (ko) | 연조직 종양의 치료 및/또는 진단 방법 | |
DK0443963T3 (da) | Detektor for strømning af en første væske i et kredsløb for cirkulation af en anden væske | |
ITFI20020208A1 (it) | Apparecchiatura utilizzabile in trattamenti di emofiltrazione. | |
MX155537A (es) | Sistema terapeutico para tratamiento extracorporal | |
ES2211996T3 (es) | Agentes de union a receptores de acido hialuronico y su uso para el tratamiento de tumores o de reestenosis. | |
ES2038064B1 (es) | Instalacion portatil de vacunacion aviar. | |
Kew, MC, Bersohn, I., Peter, J., Wyndham, CH & Seftel | Preliminary observations on the serum and cerebrospinal fluid enzymes in heatstroke | |
ATE86498T1 (de) | Verminderung des gehaltes an lipoproteine mit geringer dichte in biologischen fluessigkeiten. | |
EA199800821A1 (ru) | Способ лечения аутизма | |
SU1563707A1 (ru) | Способ лечени гнойно-септических заболеваний | |
RU1806785C (ru) | Способ обработки крови | |
ES2085411T3 (es) | Uso de heptastigmina en la terapia de ictus cerebral. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 567514 Country of ref document: ES |